- Conditions
- Dry Eye
- Interventions
- Brimonidine, Brimonidine Mono Therapy, sodium carboxymethylcellulose, Corticosteroid Eye Drop
- Drug
- Lead sponsor
- Ocugen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 84 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2018
- U.S. locations
- 3
- States / cities
- Hoffman Estates, Illinois • Yorkville, Illinois • Salt Lake City, Utah
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–13
of 13
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Dry Eye
- Interventions
- Brimonidine Tartrate, Placebos
- Drug
- Lead sponsor
- Ocugen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 252 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 16
- States / cities
- Newport Beach, California • Rancho Cordova, California • Pompano Beach, Florida + 11 more
- Conditions
- COVID-19
- Interventions
- BBV152
- Biological
- Lead sponsor
- Ocugen
- Industry
- Eligibility
- 18 Years to 65 Years
- U.S. locations
- 1
- States / cities
- Langhorne, Pennsylvania
- Conditions
- Stargardt Disease
- Interventions
- OCU410ST
- Drug
- Lead sponsor
- Ocugen
- Industry
- Eligibility
- 5 Years and older
- Enrollment
- 51 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 14
- States / cities
- Phoenix, Arizona • Sacramento, California • Gainesville, Florida + 11 more
- Conditions
- Center Involved Diabetic Macular Edema, Diabetic Macular Edema
- Interventions
- OCU200
- Drug
- Lead sponsor
- Ocugen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2026
- U.S. locations
- 5
- States / cities
- Deerfield Beach, Florida • Erie, Pennsylvania • Bellaire, Texas + 2 more
- Conditions
- Retinitis Pigmentosa
- Interventions
- Sub-Retinal Administration of OCU400-301
- Genetic
- Lead sponsor
- Ocugen
- Industry
- Eligibility
- 3 Years and older
- Enrollment
- 140 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 12
- States / cities
- Phoenix, Arizona • La Jolla, California • Los Angeles, California + 9 more
- Conditions
- Retinitis Pigmentosa
- Interventions
- OCU400
- Drug
- Lead sponsor
- Ocugen
- Industry
- Eligibility
- 18 Years to 99 Years
- U.S. locations
- 5
- States / cities
- Phoenix, Arizona • Deerfield Beach, Florida • Erie, Pennsylvania + 2 more
- Conditions
- Dry Eye, Ocular Graft vs Host Disease, Meibomian Gland Dysfunction
- Interventions
- Brimonidine 0.15%, Brimonidine 0.075%, Placebo
- Drug
- Lead sponsor
- Sandeep Jain, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 2
- States / cities
- Chicago, Illinois
- Conditions
- COVID-19
- Interventions
- BBV152
- Biological
- Lead sponsor
- Ocugen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 400 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2023
- U.S. locations
- 10
- States / cities
- Tempe, Arizona • Miami, Florida • Miami Lakes, Florida + 6 more
- Conditions
- Graft Versus Host Disease, Ocular Surface Disease, oGVHD, Ocular Graft vs Host Disease, Brimonidine Tartrate, Lubricant Eye Drops, Ophthalmic Solutions, Graft vs Host Disease
- Interventions
- Brimonidine Tartrate, Placebos
- Drug
- Lead sponsor
- Ocugen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 59 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 13
- States / cities
- Phoenix, Arizona • Palo Alto, California • Atlanta, Georgia + 10 more
- Conditions
- Retinitis Pigmentosa, Leber Congenital Amaurosis
- Interventions
- OCU400 Low Dose, OCU400 Med Dose, OCU400 High Dose, OCU400 Second Eye Dosing
- Drug
- Lead sponsor
- Ocugen
- Industry
- Eligibility
- 6 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 7
- States / cities
- Phoenix, Arizona • La Jolla, California • Miami, Florida + 4 more
- Conditions
- Geographic Atrophy
- Interventions
- OCU410
- Genetic
- Lead sponsor
- Ocugen
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2030
- U.S. locations
- 12
- States / cities
- Phoenix, Arizona • Coral Springs, Florida • Carmel, Indiana + 9 more
- Conditions
- Dry Age-related Macular Degeneration
- Interventions
- OCU410
- Biological
- Lead sponsor
- Ocugen
- Industry
- Eligibility
- 55 Years and older
- Enrollment
- 237 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 3
- States / cities
- Phoenix, Arizona • Erie, Pennsylvania • McAllen, Texas